This design was supported by studies that identified synergy when CD47 and PD-L1 antibodies were combined, and others that combined CD47 mAbs with antibodies targeting tumor-specific markers such as CD20 in lymphoma models [258]. This evidence concerns the gene CD274 and neoplasm.